Applying the Estimands Framework to Optimize Development of Disease-Modifying Therapies

Mon, Aug 7, 10:30 AM

Biopharmaceutical Section

4 Presentations

10:35 AM - 10:55 AM

Yongming Qu (Eli Lilly and Company)

10:55 AM - 11:15 AM

Craig Mallinckrodt (Pentara Corp, Millcreek UT)

11:15 AM - 11:35 AM

Lamar Hunt (Johnson & Johnson)

11:35 AM - 11:55 AM

Geert Molenberghs (Universiteit Hasselt & Katholieke Universiteit Leuven)

Sue-Jane Wang (FDA/Office of Biostatistics, Office of Translational Sciences, CDER)